Press Release

Morgan Lewis Advises PTC Therapeutics on Acquisition of Censa Pharmaceuticals

Friday, May 8, 2020

PHILADELPHIA, May 8, 2020: Morgan Lewis represented PTC Therapeutics Inc. in its acquisition of Censa Pharmaceuticals Inc.

PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Censa is a biopharmaceutical company focused on the development of a clinical-stage investigational therapy for orphan metabolic diseases.

Partners Richard Aldridge and David Glazer and of counsel Veronica DiCamillo represented PTC.

For more, read PTC’s announcement.